tri-cyclen and Obesity

tri-cyclen has been researched along with Obesity* in 2 studies

Trials

2 trial(s) available for tri-cyclen and Obesity

ArticleYear
Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women.
    Fertility and sterility, 2011, Volume: 96, Issue:2

    To evaluate the effects of a commonly used combined hormonal oral contraceptive (OC) on carbohydrate metabolism in obese as compared with lean women.. 6-month prospective study.. Clinical research center at an academic medical center.. Premenopausal nondiabetic women with body mass index <25 kg/m(2) (n = 15) or >30 kg/m(2) (n = 14).. Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles.. Insulin sensitivity by frequent sampling intravenous glucose tolerance test; other indices of insulin sensitivity (homeostatic model assessment of insulin sensitivity index [ISI HOMA], the Matsuda index); fasting lipid panel.. Insulin sensitivity changed from 6.62 ± 3.69 min(-1)/mIU/L (baseline) to 8.23 ± 3.30 min(-1)/mIU/L (6 months) in lean women, and from 4.36 ± 2.32 to 3.82 ± 2.32 min(-1)/mIU/L in obese women. Divergent effects on insulin sensitivity were also observed with ISI HOMA and the Matsuda index. Low-density lipoprotein increased by approximately 20 mg/dL in both the lean and obese groups.. Lean and obese women exhibit differential changes in insulin sensitivity when given 6 months of a commonly used oral contraceptive. The mechanisms of these differences and whether these divergent effects persist in the long term require further investigation.

    Topics: Academic Medical Centers; Adult; Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Administration Schedule; Drug Combinations; Ethinyl Estradiol; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Lipoproteins, LDL; Norgestrel; Obesity; Prospective Studies; Thinness; Time Factors; Virginia; Young Adult

2011
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
    Fertility and sterility, 2011, Volume: 96, Issue:2

    In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.

    Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Endothelium, Vascular; Ethinyl Estradiol; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Metformin; Norgestrel; Obesity; Overweight; Placebo Effect; Polycystic Ovary Syndrome; Time Factors; Treatment Outcome; Vasodilation; Virginia

2011